||MT2012-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
||Endpoints include time to engraftment, incidence of graft failure, incidence of chimerism at 100 days, 6 months, and 1 year; incidence of acute graft-versus-host disease (GVHD) at 100 days and chronic GVHD at 6 months and 1 year; incidence of transplant related mortality at 6 months and incidence of disease free survival and overall survival at 6 months.
||Based on diagnosis and clinically history, a determination of the most appropriate regimen will be made based on the following prep plans:
Arm A: Fully Myeloablative Preparative Regimen
Arm B: Reduced Toxicity Ablative Preparative Regimen
Arm C: Reduced Intensity Conditioning
Arm D: No Preparative Regimen
||This is a treatment guideline for allogeneic hemapoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
||Diagnosis of immunodeficiency or histiocytic disorder.
|Applicable Disease Sites
||Blood and Marrow Transplant
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
||Masonic Cancer Center
||Must be no more than 50 years of age and have an identified stem cell source. Adequate organ function is required. Women who are pregnant or nursing are not eligible. Anyone with an active uncontrolled infection, HIV positive, or acute hepatitis is not eligible. A signed informed consent and HIPAA authorization are required.